Feng et al. [21] confirmed that LINC00460 was an oncogene for PTC and promoted the progression of papillary thyroid cancer by regulating miR-613, suggesting that LINC00460 may be a potential therapeutic target for papillary thyroid cancer. This evidence concerns the gene LINC00460 and thyroid gland papillary carcinoma.